digestVidSign in
summary

Dr. John Campbell - Cancer and vitamin D

Thumbnail of the video “Dr. John Campbell - Cancer and vitamin D”
Community upload. AI output has not been independently verified.
Author: Dr. John Campbell
Categories: Health Nutrition
Tags: health, nutrition
Views: 1 · Last viewed: 2026-10-13 23:15 UTC

Short Summary

Main recommendation: Measure vitamin D levels in cancer patients before starting treatment, and correct any deficiency to a level of about 100 nmol per liter (40 ng/ml), because the speaker argues that immunotherapy and other treatments work poorly in those who are deficient. The speaker cites a meta-analysis of 88,000 patients showing a 13% improvement in clinical outcome when vitamin D was corrected before treatment, compared with tamoxifen's 8% improvement.

Key Points

  • In the speaker's immunotherapy work, responders to treatment had adequate vitamin D levels and non-responders had low levels, and correcting vitamin D before treatment was linked to the benefit seen in the randomized study of IMM 101, a killed-bacteria immunotherapy.
  • A meta-analysis of 88,000 patients in trials across many cancers and treatments found a 13% clinical outcome improvement where vitamin D was corrected before treatment, versus a measure-only approach.
  • The speaker says the NHS threshold of 50 is too low because it reflects a chronically deficient general population, and argues that the functional target is over 100 nmol per liter.
  • The speaker suggests supplementing vitamin D in everyone over about 50, because cancer rates rise from that age and vitamin D supports innate immune function, and claims it may protect against flu and COVID, citing four papers suggesting vitamin D is more effective than flu vaccines at preventing flu.
  • The speaker says the medical establishment and pharmaceutical industry have not prioritized vitamin D measurement in treatment protocols.

Details Worth Noting

  • Concrete instructions: Measure vitamin D before starting cancer treatment, using the blood test the speaker describes as easy and straightforward. Supplement to bring the level into the normal range, with the speaker's target of about 100 nmol per liter (40 ng/ml). Give a dose expected to maintain that level, then recheck after about two months and adjust, which the speaker describes as a simple titration.
  • The speaker names D3 (cholecalciferol) and calciferol as the supplement forms to use.
  • The speaker says high doses (tens of thousands of units) can push levels above 200 and risk kidney stones or renal failure, since vitamin D is excreted by the kidneys. Renal failure and certain rare phosphate pathway problems can cause dangerous buildup.
  • The speaker cites a pancreatic cancer trial where IMM 101 was the only immunotherapy to show a survival benefit, and states that all patients were checked for vitamin D before randomization.
  • The speaker notes that a patient with severe deficiency had a level too low to measure accurately.

Bottom Line

The speaker argues that vitamin D status is a major, under-recognized factor in cancer treatment response and that checking and correcting it is a low-cost, low-risk step, supported by his own research, a large meta-analysis, and clinical trial data he cites.